Pharmaceutical ophthalmic compositions and uses thereof
Patent Information
- Application Number
- JP2024535940
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2021-12-17
- Filing Date
- 2022-12-16
- Publication Date
- 2024-11-29
AI Technical Summary
Current treatments for dry eye syndrome, such as artificial tears and corticosteroids, have limitations in efficacy and toxicity, and there is a need for pharmaceutical ophthalmic compositions that stabilize active ingredients like WS-12 to maximize their pharmaceutical activity while avoiding preservatives that can harm the eye.
Pharmaceutical ophthalmic compositions containing 0.0005% to 0.01% (1R,2S,5R)-2-isopropyl-N-(4-methoxyphenyl)-5-methylcyclohexane-1-carboxamide (WS-12) with solubilizers, viscosity modifiers, buffers, and tonicity agents, formulated to maintain stability and bioavailability, and packaged to protect against environmental factors.
The compositions effectively treat dry eye symptoms by increasing tear production, reducing discomfort, and maintaining WS-12 stability during storage, even at ambient temperatures, without the need for refrigeration.
Smart Images

Figure 2024544393000015 
Figure 2024544393000016 
Figure 2024544393000017
Abstract
Citation Information
Patent Citations
Chroman derivative-containing eye drop
JP1999130675A
Ophthalmic composition with regulated viscosity
JP2008195720A
Pharmaceutical composition
JP2011213667A
Plastic oil and fat composition and food to which plastic oil and fat composition is added
JP2016131559A
Ophthalmic composition for treating dry eye and symptoms thereof
US20200306218A1
